Natural products for COVID-19 prevention and treatment regarding to previous coronavirus infections and novel studies
- PMID: 32985017
- DOI: 10.1002/ptr.6873
Natural products for COVID-19 prevention and treatment regarding to previous coronavirus infections and novel studies
Abstract
Recently, the novel life-threatening coronavirus infection (COVID-19) was reported at the end of 2019 in Wuhan, China, and spread throughout the world in little time. The effective antiviral activities of natural products have been proved in different studies. In this review, regarding the effective herbal treatments on other coronavirus infections, promising natural products for COVID-19 treatment are suggested. An extensive search in Google Scholar, Science Direct, PubMed, ISI, and Scopus was done with search words include coronavirus, COVID-19, SARS, MERS, natural product, herb, plant, and extract. The consumption of herbal medicine such as Allium sativum, Camellia sinensis, Zingiber officinale, Nigella sativa, Echinacea spp. Hypericum perforatum, and Glycyrrhiza glabra, Scutellaria baicalensis can improve the immune response. It seems that different types of terpenoids have promising effects in viral replication inhibition and could be introduced for future studies. Additionally, some alkaloid structures such as homoharringtonine, lycorine, and emetine have strong anti-coronavirus effects. Natural products can inhibit different coronavirus targets such as S protein (emodin, baicalin) and viral enzymes replication such as 3CLpro (Iguesterin), PLpro (Cryptotanshinone), helicase (Silvestrol), and RdRp (Sotetsuflavone). Based on previous studies, natural products can be introduced as preventive and therapeutic agents in the fight against coronavirus.
Keywords: 3CLpro inhibitors; ACE2; COVID-19; PLpro inhibitors; coronavirus; natural products.
© 2020 John Wiley & Sons Ltd.
References
REFERENCES
-
- Brojakowska, A., Narula, J., Shimony, R., & Bander, J. (2020). Clinical implications of SARS-Cov2 interaction with renin angiotensin system. Journal of the American College of Cardiology, 75, 3085-3095.
-
- Cao, J., Forrest, J. C., & Zhang, X. (2015). A screen of the NIH clinical collection small molecule library identifies potential anti-coronavirus drugs. Antiviral Research, 114, 1-10.
-
- Cascella, M., Rajnik, M., Cuomo, A., Dulebohn, S. C., & Di Napoli, R. (2020). Features, evaluation and treatment coronavirus (COVID-19), StatPearls [internet], Treasure Island: StatPearls Publishing.
-
- Chan, J. F.-W., Kok, K.-H., Zhu, Z., Chu, H., To, K.K.-W, Yuan, S., & Yuen, K.-Y. (2020). Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerging Microbes & Infections, 9, 221-236.
-
- Chan, J. F., Lau, S. K., To, K. K., Cheng, V. C., Woo, P. C., & Yuen, K.-Y. (2015). Middle East respiratory syndrome coronavirus: Another zoonotic betacoronavirus causing SARS-like disease. Clinical Microbiology Reviews, 28, 465-522.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
